ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Interleukins"

  • Abstract Number: 0303 • ACR Convergence 2024

    Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2

    Laura K. Ferris1, Jerry Bagel2, Yu-Huei Huang3, Andrew E. Pink4, Stephen K. Tyring5, Georgios Kokolakis6, Amy M. DeLozier7, Daniel Kakaley8, Shu Li9, Yaung-Kaung Shen10, Takayuki Ota7 and Robert Bissonnette11, 1University of Pittsburgh, Pittsburgh, PA, 2Psoriasis Treatment Center of Central NJ, East Windsor, NJ, 3Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), 4NHS Foundation Trust Great Maze Pond, London, United Kingdom, 5Center for Clinical Studies, Webster, TX, 6Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Janssen Research & Development, LLC, San Diego, CA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Innovaderm Research, Montreal, QC, Canada

    Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
  • Abstract Number: 2597 • ACR Convergence 2024

    The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation

    Jia (Sijia) Chen1, Roopa Madhu2, Catherine Manning3, Daniel Montoro4, Nataliya Yeremenko5, Kevin Wei6, ilya Korsunsky1, Dominique Baeten5 and Ellen Gravallese7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Brookline, MA, 3Brigham and Women's Hospital, Dedham, MA, 4TenSixty Biosciences, Boston, MA, 5Amsterdam University Medical Centers, Amsterdam, Netherlands, 6Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 7Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
  • Abstract Number: 0562 • ACR Convergence 2024

    Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study

    Lucia Ondrejčáková1, Adéla Navrátilová2, Monika Gregová3, Kristýna Bubová4, Tomáš Grega5, Ladislav Šenolt6, Karel Pavelka7 and Lucie Andrés Cerezo8, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, 21st Faculty of Medicine, Charles University and Institute of Rheumatology in Prague, Hlavní mesto Praha, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine Charles University, Prague, Czech Republic, 4Institute of Rheumatology and Charles University, Prague, Czech Republic, 53Department of Internal Medicine, First Faculty of Medicine, Charles University, Military University Hospital, Prague, Czech Republic, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 7Institute of Rheumatology and Charles University, Praha, Czech Republic, 8Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA)…
  • Abstract Number: 2616 • ACR Convergence 2024

    Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases

    Jeffrey Sparks1, Xiaosong Wang2, Pui Lee3, Kailey Brodeur4, Miao Lin5, Naomi Patel5, Yumeko Kawano6, Abigail Schiff7, Andrew King5, Jennifer Hanberg6, Shruthi Srivatsan5, Emily Kowalski6, Colebrook Johnson5, Kathleen Vanni6, Zachary Williams5, Grace Qian2, Caleb Bolden5, Kevin Mueller6, Katarina Bade6, Alene Saavedra6, Rathnam Venkat8 and Zachary Wallace9, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Boston Children's Hospital, Newton, MA, 4Boston Children's Hospital, Cumberland, RI, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital, Cambridge, MA, 8Tufts University School of Medicine, Boston, MA, 9Massachusetts General Hospital, Newton, MA

    Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
  • Abstract Number: 0585 • ACR Convergence 2024

    Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry

    Alexis Ogdie1, Nicole Middaugh2, Maya Marchese2, Jessica A Walsh3, Natalia Bello4, Jeffrey Lisse4, Andris Kronbergs5, Elsie Grace6, Marcus Ngantcha4 and Philip Mease7, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2CorEvitas, LLC, Waltham, MA, 3Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, 4Eli Lilly and Company, Indianapolis, IN, 5Eli Lilly, Indianapolis, IN, 6Eli Lilly and Company, Indianapolis, 7Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
  • Abstract Number: 2646 • ACR Convergence 2024

    Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries

    Yosuke Kunishita1, Urvashi Kaundal2, Martin Kerick3, Ryan Routsong4, Justin Lack4, Ami Shah5, Maureen Mayes6, Daniel Shriner7, Ayo P. Doumatey7, Amy Bentley7, Robyn Domsic8, Thomas Medsger, Jr9, Paula Ramos10, Richard Silver11, Virginia Steen12, John Varga13, Vivien Hsu14, Lesley Ann Saketkoo15, Dinesh Khanna13, Elena Schiopu16, Jessica Gordon17, Lindsey Criswell18, Heather Gladue19, Chris Derk20, Elana Bernstein21, S. Louis Bridges17, Victoria Shanmugam22, Lorinda Chung23, Suzanne Kafaja24, Reem Jan25, Marcin Trojanowski26, Avram Goldberg27, Benjamin Korman28, James W. Thomas29, Elaine Remmers30, Adebowale Adeyemo7, Charles Rotimi7, Fredrick Wigley31, Francesco Boin32, Javier Martin3, Daniel Kastner33 and Pravitt Gourh34, 1Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Scleroderma Genomics and Health Disparities Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Chevy Chase, MD, 3Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, 4Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 5Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 6UTHealth Houston Division of Rheumatology, Houston, TX, 7Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 9Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, 10Medical University of South Carolina, Charleston, SC, 11Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, 12Georgetown University School of Medicine, Washington, DC, 13University of Michigan, Ann Arbor, MI, 14Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, 15New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, 16Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, 17Division of Rheumatology, Weill Cornell Medical College, New York, NY, 18Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, 19Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 20Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 21Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 22Office of Autoimmune Disease Research, Office of Research on Women's Health, National Institutes of Health, Great Falls, VA, 23Stanford University, Woodside, CA, 24Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 25Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, 26Department of Rheumatology, Boston University School of Medicine, Boston, MA, 27NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, 28University of Rochester, Rochester, NY, 29NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 30Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 31Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 32Cedars-Sinai Medical Center, Los Angeles, CA, 33National Human Genome Research Institute, Bethesda, MD, 34National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by systemic inflammation and fibrosis. Interleukin-1 receptor accessory protein (IL1RAP) is a co-receptor for the Interleukin-1…
  • Abstract Number: 0909 • ACR Convergence 2023

    Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus

    Joy Park1, Xiaojing Wang2, Aparna Godavarthy1, Akshay Patel2, Krakko Daniel1, Jessica Nolan1, Joanne Chilton1, Bryan Blaker1 and Andras Perl3, 1Upstate Medical University, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3SUNY, Syracuse, NY

    Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
  • Abstract Number: 2245 • ACR Convergence 2023

    Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study

    Lars Erik1, Kim A Papp2, Andrew Östör3, Vassilis Stakias4, Tshepiso Madihlaba4, Ralph Lippe5, Ran Liu4 and Diamant Thaçi6, 1Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 2Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada, 3Monash University & Emeritus Research; Australian National University, Melbourne, Australia, 4AbbVie, Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 6Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

    Background/Purpose: Risankizumab (RZB) is an optimized IL-23 inhibitor (IL-23i) currently approved for the treatment of plaque psoriasis (PsO), PsA, and Crohn's disease. In a post…
  • Abstract Number: 0937 • ACR Convergence 2023

    IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice

    Ji Won Yang1, Kun Hee Lee2, Jin Seok Woo2, Ha Yeon Jeong2, JeongWon Choi2, Eui-Jong Kwon1, Mi-La Cho2 and Sung-Hwan Park1, 1Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 2Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Systemic sclerosis (SS), also known as scleroderma, is a chronic autoimmune disease caused by inflammation, tissue fibrosis, and vasculopathy. Although the pathological mechanisms of…
  • Abstract Number: 2254 • ACR Convergence 2023

    The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Ruoning Ni1, Jiayi Zheng2, Ruru Guo3 and Bharat Kumar4, 1University of Iowa Hospitals and Clinics, Coralville, IA, 2The Wright Center for Graduate Medical Education, Scranton, PA, 3Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 4University of Iowa Hospitals and Clinics, Iowa City, IA

    Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis…
  • Abstract Number: 1266 • ACR Convergence 2023

    The Anti-inflammatory Effect of High-density Lipoprotein Is Blunted by Delivery of Altered MicroRNA Cargo to Macrophages in Patients with Rheumatoid Arthritis

    Qiong Wu, Quanhu Sheng, Danielle Michell, Marisol Ramirez-Solano, Olivia Posey, Anastasiia Phothisane, Shahensha Shaik, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: High-density lipoprotein (HDL) has well-characterized anti-atherogenic cholesterol efflux and antioxidant functions. Another function of HDL uncharacterized in RA is its ability to transport microRNAs…
  • Abstract Number: 2447 • ACR Convergence 2023

    Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus

    Joshua Reynolds1, Michelle Huang1, Myriam Meineck2, Tamara Möckel2, Andreas Schwarting2 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany

    Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) in the form of cognitive deficits, memory loss, depression, and anxiety.…
  • Abstract Number: 1324 • ACR Convergence 2023

    Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK

    Roxanne Cooksey1 and Ernest Choy2, 1Cardiff University, Cardiff, United Kingdom, 2Section of Rheumatology, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
  • Abstract Number: 2475 • ACR Convergence 2023

    Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders

    Kailey Brodeur1, Meng Liu2, Yan Du3, Lauren Henderson1, Joyce Chang1, Jane Newburger1, Peter Nigrovic1 and Pui Lee4, 1Boston Children's Hospital, Boston, MA, 2Southern Medical University, Boston, MA, 3Harvard medical school, Boston, MA, 4Division of Immunology, Boston Children's Hospital, Boston, MA

    Background/Purpose: Kawasaki disease (KD) is a systemic vasculitis of young children that can lead to the development of coronary artery aneurysms (CAA) in up to…
  • Abstract Number: 1422 • ACR Convergence 2023

    Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data

    Kenneth Gordon1, Andrew Blauvelt2, Herve Bachelez3, Laura Coates4, Blair Kaplan5, Willem Koetse5, Leonidas Drogaris5, Ranjeeta Sinvhal5 and Kim A Papp6, 1Medical College of Wisconsin, Milwaukee, WI, 2Oregon Medical Research Center, Portland, OR, 3APHP Hopital Saint-Louis, Universite de Paris, Paris, France, 4University of Oxford, Oxford, United Kingdom, 5AbbVie, Inc., North Chicago, IL, 6Alliance Clinical Research and Probity Medical Research, Waterloo, and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Risankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinical trials.The objective of this integrated data…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology